Related Experiment Videos
Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction
1College of Pharmacy, North Dakota State University, Fargo 58105.
Abstract:
Ceftazidime, a beta-lactamase-stable, third-generation cephalosporin, is widely used for the treatment of serious gram-negative infections. Neurotoxicity has rarely been associated with the drug; however, two of our patients developed ceftazidime-induced neurotoxicity that produced confusion, disorientation, agitation, generalized weakness, and myoclonus. In both patients these symptoms cleared with either discontinuation or reduction of the dosage of ceftazidime. This emphasizes the importance of adjusting the dosage of ceftazidime in patients with renal insufficiency.
Insights
Ceftazidime, a third-generation cephalosporin antibiotic, can rarely cause neurotoxicity. Adjusting dosage in patients with kidney problems is crucial to prevent adverse neurological effects like confusion and weakness.
Area of Science:
- Pharmacology
- Neuroscience
- Infectious Diseases
Background:
- Ceftazidime is a third-generation cephalosporin antibiotic.
- It is commonly used for serious gram-negative bacterial infections.
- Neurotoxicity is a rare but potential adverse effect.